Front. Cell. Infect. Microbiol.Frontiers in Cellular and Infection MicrobiologyFront. Cell. Infect. Microbiol.2235-2988Frontiers Media S.A.10.3389/fcimb.2023.1184922Cellular and Infection MicrobiologyEditorialEditorial: Alternative approaches to antifungal drugs against drug-resistant fungiKovácsRenátó1*†MahmoudiShahram2*†1Department of Medical Microbiology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary2Department of Parasitology and Mycology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
Edited and Reviewed by: Anuradha Chowdhary, University of Delhi, India
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
Editorial on the Research Topic Alternative approaches to antifungal drugs against drug-resistant fungifungialternative therapeutic approachCandidaAspergillusresistance
In the last two decades, the uncontrolled widespread usage of different antifungal agents in veterinary and human medicine as well as in agriculture has significantly changed the epidemiological landscape of invasive fungal infections, where fungal species showing multi – or panresistant isolates are steadily increasing. This worrisome trend can be observed in the worldwide emergence of difficult to treat azole-resistant Aspergillus fumigatus, Candida auris and multidrug-resistant C. glabrata (Arastehfar et al., 2020). Therefore, the World Health Organization published the list of fungal priority pathogens in 2022, which is the first global effort to systematically classify various fungal pathogens considering their current public health importance. In this report, C. albicans, C. auris, A. fumigatus and Cryptococcus neoformans were assigned to the critical priority group (WHO, 2022).
The number of novel antifungal drugs have been scarce over the last years, and only three agents can be found at least in phase 3 clinical trial such as rezafungin, oteseconazole and ibrexafungerp. The latter compound has been already approved in 2021 by the U.S. Food and Drug Administration for the treatment of vulvovaginal candidiasis (McCarty and Pappas). Therefore, it is necessary to discover and introduce new antifungal agents and/or alternative therapeutic approaches in clinical practice (Kovács and Majoros, 2020; Izadi et al., 2022; Lamoth, 2023).
This Special Issue addresses current innovative investigations regarding alternative antifungal therapies against potentially resistant fungal species. A total of four original articles were published in this Special Issue. Schwarz et al. tested the in vitro interaction of isavuconazole and colistin against various clinically relevant Candida species. Based on calculated fractional inhibitory concentration indices, the combination was synergistic in 50%, 80%, 90%, and 90% of the C. kefyr, C. krusei, C. glabrata, and C. tropicalis isolates tested, respectively. Isavuconazole with colistin against C. albicans and C. parapsilosis exhibited only indifferent interaction for 100% and 90% of the isolates, respectively. Moreover, antagonistic interaction was never observed. Plants are rich source of several aromatic bioactive compounds, which can facilitate the development of novel innovative antifungal strategies for the effective treatment of fungal pathogens. Regarding these compounds Lee et al. showed that curcumin triggered a decrease in Hsp90 by affecting it at the post-transcriptional level, which lead to the down-regulated level of HOG1 and CDR1 genes. This resulted in a decrease of the stress response and efflux pump activity as well as impair cell growth in C. albicans. In the past years, Caesalpinia bonduc has received increasing attention thanks to its wide spectrum antimicrobial effects. Sasidharan et al. examined ethanolic extracts of C. bonduc seeds (EECS) against four Candida species in vitro and in vivo. The EECS treatment exerted oxidative stress in Candida cells, which resulted the increase of cytoplasma membrane permeability of C. albicans and caused mitochondrial dysfunction. In Galleria mellonella model, the EECS treatment considerably increase the recovery rate of G. mellonella larvae following the treatment. The resistant phenotype is frequently associated with the biofilm forming ability. These sessile communities possess with higher resistance to environmental factors, immune response and antimicrobial agents (Ciofu et al., 2022). Regarding filamentous fungi, Sen et al. elucidated the antibiofilm properties of 4-allyl-2-methoxyphenol (eugenol) against ten soil-derived azole-resistant A. fumigatus isolates. Eugenol exhibited antibiofilm activity against these resistant isolates, ranging from 312 to 500 µg/mL. Surprisingly, the eugenol treatment was associated with absence of extracellular matrix of A. fumigatus biofilm. Furthermore, eugenol significantly decrease the transcription level of some efflux pumps genes including MDR1 and MDR4.
In summary, this Special Issue is a great resource that presents novel research concerning alternative treatment strategies against clinically relevant fungal species. Hopefully, these published results will be able to stimulate further state-of-the-art studies in the future.
Author contributions
RK and SM were guest associate editors of the Research Topic. They wrote and edited the paper text. All authors contributed to the article and approved the submitted version.
Funding
RK was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00127/21/8). This research was supported by the Hungarian National Research, Development and Innovation Office (NKFIH FK138462). RK was supported by the UNKP-22-5-DE-417 New National Excellence Program of the Ministry for Innovation and Technology from the Source of the National Research, Development and Innovation Fund.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
ReferencesArastehfarA.GabaldónT.Garcia-RubioR.JenksJ. D.HoeniglM.SalzerH. J. F.. (2020). Drug-resistant fungi: An emerging challenge threatening our limited antifungal armamentarium. Antibiotics (Basel).9, 877. doi: 10.3390/antibiotics9120877WHO. (2022). WHO fungal priority pathogens report. Available at: https://www.who.int/publications/i/item/9789240060241.CiofuO.MoserC.JensenPØHøibyN. (2022). Tolerance and resistance of microbial biofilms. Nat. Rev. Microbiol.20, 621–635. doi: 10.1038/s41579-022-00682-4IzadiA.Aghaei GharehbolaghS.SadeghiF.TalebiM.DarmianiK.ZarrinniaA.. (2022). Drug repurposing against candida auris: A systematic review. Mycoses.65, 784–793. doi: 10.1111/myc.13477KovácsR.MajorosL. (2020). Fungal quorum-sensing molecules: A review of their antifungal effect against candida biofilms. J. Fungi (Basel).6, 99. doi: 10.3390/jof6030099LamothF. (2023). Novel therapeutic approaches to invasive candidiasis: Considerations for the clinician. Infect. Drug Resist.16, 1087–1097. doi: 10.2147/IDR.S375625